Loading...
NPI 1154089241 · Brooklyn, NY · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Fast Lab Technologies LLC is a clinical medical laboratory provider located in Brooklyn, New York. This profile covers 2 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Fast Lab Technologies LLC |
| Address | 215 Water St |
| City | Brooklyn |
| State | NY |
| ZIP | 11201 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 6, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $9.3M |
| Medicaid | $6.1M |
FAST LAB TECHNOLOGIES LLC operates squarely as a high-volume clinical testing laboratory focused on SARS-CoV-2 diagnostics: its top-billed codes are 87811 (immunoassay detection of SARS–CoV–2) and 87635 (amplified nucleic acid probe for SARS–CoV–2), and Medicaid billing also includes high-throughput code U0003 and specimen-collection G2023, indicating an end-to-end COVID-19 testing workflow consistent with its Clinical Medical Laboratory taxonomy. The mix of immunoassay, NAAT, high-throughput nucleic acid testing, and specimen-collection codes points to a lab-sized operation rather than a point-of-care clinic.
Medicare revenue is highly concentrated in COVID-19 testing: total Medicare revenue is $9.3M and the precomputed top three Medicare codes account for 100.0% of that revenue, with 87811 reporting $7.1M (75.6% of this provider's total Medicare revenue) and 87635 reporting $2.3M (24.4% of this provider's total Medicare revenue). This means Medicare receipts for this NPI are driven almost entirely by those two SARS–CoV–2 test codes.
Medicaid billing shows a similar concentration: total Medicaid revenue is $6.1M and the precomputed top three Medicaid codes account for 92.3% of that revenue, led by 87811 at $3.6M (58.8%), 87635 at $1.1M (18.3%), and U0003 at $933K (15.2%). The Medicaid mix retains the same primary COVID-19 testing focus but is slightly more diversified within the top three codes than Medicare.
The provider participates meaningfully in both payer channels rather than being single-payer: Medicare receipts ($9.3M) exceed Medicaid receipts ($6.1M), so Medicare is the larger source of lifetime public-payer revenue on file, but Medicaid remains a substantial secondary revenue stream and includes additional service codes such as G2023 ($255.9K, 4.2% of Medicaid revenue) and U0005 ($216.3K, 3.5% of Medicaid revenue). This dual-payer footprint suggests operational capacity to serve both Medicare and Medicaid populations at scale.
FAST LAB is a competitive outlier on its top COVID-19 codes at both national and state levels: for Medicare, 87811 ranks #1 of 10132 providers nationally and 87635 ranks #1 of 9976 providers nationally (both listed as 100th percentile and described as extreme outliers), indicating facility-level volumes far above typical national providers for these tests. For Medicaid, 87811 ranks #1 of 394 providers in-state (100th percentile; extreme outlier) and 87635 ranks #5 of 944 providers in-state (100th percentile; extreme outlier), characterizing the lab as a dominant in-state provider for immunoassay testing and a top-five provider for NAAT.
Other Medicaid code ranks reflect routine volumes for complementary services: U0003 is ranked #45 of 336 providers in-state (87th percentile; typical, unremarkable volume), G2023 is #13 of 484 (98th percentile; typical, unremarkable volume), and U0005 is #50 of 297 (83th percentile; typical, unremarkable volume). These placements suggest that while the lab is unusually large for the primary SARS–CoV–2 assays, its use of certain high-throughput and specimen-collection codes is within expected ranges for in-state peers.
Reimbursement patterns differ materially by payer on a per-claim basis: Medicare average paid/claim for the two main codes is $41 (87811) and $50 (87635), while Medicaid average paid/claim is lower at $13 (87811) and $18 (87635). This gap indicates the provider’s revenue mix and profitability per test will be influenced not only by volume but by the higher per-claim Medicare rates versus Medicaid rates.
The NPI tenure is relatively recent—enumerated on 2021-12-06 (~5 years ago)—and yet the entity has scaled to high-volume testing quickly, as evidenced by hundreds of thousands of claims reported on key codes (e.g., Medicaid 87811 at 277.3K claims and Medicare 87811 at 173.6K claims). Rapid growth to a dominant national and in-state position on core COVID-19 test codes within this timeframe suggests a pandemic-era buildout of laboratory capacity rather than a long-established, diversified testing enterprise.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 173,630 | $40 | $7.1M |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 45,900 | $50 | $2.3M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 2 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 277,260 | $10 | $3.6M |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 62,150 | $20 | $1.1M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 21,700 | $40 | $933K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 23,260 | $10 | $255.9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 18,030 | $10 | $216.3K |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 45 | 340 | 1,090 | $70 | $1.4M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 50 | 300 | 1,710 | $20 | $458.6K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 5 | 940 | 220 | $30 | $89.4K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 1 | 390 | 160 | $20 | $62K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 13 | 480 | 190 | $10 | $49K |
Other providers in the same ZIP code as Fast Lab Technologies LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.